기본 통계
| LEI | 549300DQ13KM0J4E2H36 |
| CIK | 1160308 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| April 24, 2026 |
mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. |
|
| April 24, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 24, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box : ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 10, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2026 SAVARA INC. |
|
| March 13, 2026 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.41 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of January 26, 2025, is entered i |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. |
|
| March 13, 2026 |
SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 4.22 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October [●], 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “H |
|
| March 13, 2026 |
EX-10.1 Exhibit 10.1 AGREEMENT OF LEASE ML7 YARDLEY PARTNERS, LP, a Pennsylvania limited partnership, as Landlord with SAVARA INC. a Delaware corporation as Tenant The Tannery 19 West College Avenue Yardley, Pennsylvania 19067 THIS AGREEMENT OF LEASE, made as of the 10th day of March 2026, by and between ML7 YARDLEY PARTNERS, LP, a Pennsylvania limited partnership (“Landlord”) and SAVARA INC., a D |
|
| March 13, 2026 |
Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of registered securities of Savara Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our amended and res |
|
| March 13, 2026 |
Exhibit 10.39 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. Purchase And Sale Agreement By and Between Savara Inc. and 4010 Royalty Investments ICAV, an Umbrella Irish collective asset-management vehicle with segrega |
|
| March 13, 2026 |
SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.40 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of October 17, 2025 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Yasmine Wasfi (“Executive”). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm |
|
| January 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 26, 2026 SAVARA INC. |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2026 SAVARA INC. |
|
| January 9, 2026 |
EX-99.1 Corporate Overview January 2026 Developing new therapies for rare respiratory diseases Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “inten |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| October 30, 2025 |
23,809,524 Shares of Common Stock Pre-Funded Warrants to Purchase 7,142,857 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279274 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024) 23,809,524 Shares of Common Stock Pre-Funded Warrants to Purchase 7,142,857 Shares of Common Stock We are offering 23,809,524 shares of our common stock, $0.001 par value per share, in this offering. We are also offering to certain of our existing large inve |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 SAVARA INC. |
|
| October 30, 2025 |
EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October 31, 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (t |
|
| October 30, 2025 |
EX-1.1 Exhibit 1.1 23,809,524 Shares of Common Stock Pre-Funded Warrants to Purchase 7,142,857 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT October 29, 2025 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 350 North 5th Street, Suite 1000 Minneapolis, Minnesota |
|
| October 30, 2025 |
SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pa., October 29, 2025—Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, |
|
| October 29, 2025 |
EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) — RTW Committed $75M in Launch Funding, Subject to U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI — — Royalties Based on Annual Net Sales of MOLBREEVI in the U.S. — — Funds Will Strengthen the Compan |
|
| October 29, 2025 |
EX-99.2 Corporate Overview October 2025 © Savara Inc. All Rights Reserved. Exhibit 99.2 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticip |
|
| October 29, 2025 |
Subject to Completion, Dated October 29, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279274 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell t |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2025 SAVARA INC. |
|
| September 2, 2025 |
EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 SAVARA INC. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2025 SAVARA INC. |
|
| May 27, 2025 |
EX-99.1 Exhibit 99.1 SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) LANGHORNE, Pa. — May 27, 2025 — Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2025 SAVARA INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| May 13, 2025 |
Composite Amended and Restated Certificate of Incorporation, as amended, of the Registrant. Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1. |
|
| May 13, 2025 |
Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. Certain information contained in this exhibit has been redacted where indicated because disclosure of such information would constitute a clearly unwarranted |
|
| April 25, 2025 |
Insider Trading and Disclosure Policy. Exhibit 19.1 Savara Inc. Insider Trading and Disclosure Policy This Insider Trading and Disclosure Policy (this “Policy”) sets forth the policy of Savara Inc. (f/k/a Mast Therapeutics, Inc.) (the “Company”) regarding transactions by certain individuals and entities involving securities of the Company and, where applicable, the disclosure of such transactions. All references to the “Company” in thi |
|
| April 25, 2025 |
mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. |
|
| April 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2025 SAVARA INC. |
|
| March 27, 2025 |
Executive Employment Agreement, dated August 24, 2023, between Savara Inc. and Anne Erickson. Exhibit 10.39 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of August 1, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Anne Erickson (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Business Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in con |
|
| March 27, 2025 |
Master Services Agreement by and between Savara ApS and Selvita S.A., effective January 17, 2024. Exhibit 10.41 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Service Agreement (the “Agreement”) is made effective as of 17.01.2024 (“Effective Date”), by and between: SELVITA S.A |
|
| March 27, 2025 |
Exhibit 10.40 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of March 13, 2025 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Kathleen McCabe (“Executive”). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. |
|
| March 27, 2025 |
Executive Employment Agreement, dated October 15, 2024, between Savara Inc. and Braden Parker. Exhibit 10.38 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of October 15, 2024 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Braden Parker (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Commercial Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 SAVARA INC. |
|
| March 26, 2025 |
Exhibit 99.1 SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL — Includes $30M at Close to Refinance Existing Debt Facility — LANGHORNE, PA – March 26, 2025 – Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercule |
|
| February 14, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 JOINT FILING 2 p25-0485exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the ne |
|
| February 11, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc. |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2025 SAVARA INC. |
|
| January 13, 2025 |
Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2025 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “pla |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 SAVARA INC. |
|
| November 27, 2024 |
SVRA / Savara Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G 1 d891757dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) November 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| November 27, 2024 |
EX-99.A 2 d891757dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Savara Inc. Date: November 27, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. B |
|
| November 14, 2024 |
SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 finsavara.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A |
|
| November 12, 2024 |
Form of Incentive Stock Option Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of |
|
| November 12, 2024 |
Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of |
|
| November 12, 2024 |
Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| November 12, 2024 |
Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [ |
|
| November 12, 2024 |
SVRA / Savara Inc. / JENNISON ASSOCIATES LLC - SVRA09302024 13G/A Passive Investment SC 13G/A 1 SVRA09302024.txt SVRA09302024 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Na |
|
| November 12, 2024 |
Form of Nonqualified Stock Option Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [ |
|
| November 12, 2024 |
Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra |
|
| November 12, 2024 |
Form of Restricted Stock Unit Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra |
|
| November 12, 2024 |
SVRA / Savara Inc. / Adage Capital Management, L.P. - SAVARA INC. Passive Investment SC 13G/A 1 p24-3026sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the |
|
| November 8, 2024 |
SVRA / Savara Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 8, 2024 |
SVRA / Savara Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us8051111016110824.txt us8051111016110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| November 6, 2024 |
SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 savara13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| October 24, 2024 |
SVRA / Savara Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us8051111016102424.txt us8051111016102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| October 1, 2024 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through September 17, 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the |
|
| October 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par |
|
| October 1, 2024 |
As filed with the Securities and Exchange Commission on October 1, 2024 As filed with the Securities and Exchange Commission on October 1, 2024 Registration No. |
|
| August 14, 2024 |
SC 13D/A 1 geo17-savara18865.htm GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC - 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Stephanie Brecher New Enterprise Associates |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| July 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0 |
|
| July 8, 2024 |
SVRA / Savara Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us8051111016070824.txt us8051111016070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| June 28, 2024 |
26,246,720 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279274 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024) 26,246,720 Shares of Common Stock We are offering 26,246,720 shares of our common stock, $0.001 par value per share, in this offering. Our common stock is traded on The Nasdaq Global Select Market under the symbol “SVRA.” On June 27, 2024, the last reported sales |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2024 SAVARA INC. |
|
| June 28, 2024 |
Exhibit 1.1 26,246,720 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT June 27, 2024 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. Savara Inc., a Delaware corporation (the “Co |
|
| June 28, 2024 |
SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK LANGHORNE, Pa., June 28, 2024— Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 SAVARA INC. |
|
| June 26, 2024 |
EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) • Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Pl |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| June 10, 2024 |
Savara Inc. 2024 Omnibus Incentive Plan EX-10.1 Exhibit 10.1 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN 1. PURPOSE OF THE PLAN. The purpose of the 2024 Omnibus Incentive Plan (the “Plan”) is to provide favorable opportunities for directors, officers, employees, consultants or advisors employed by or providing services to Savara Inc., a Delaware corporation (the “Company”) or any of its Subsidiaries, to acquire shares of common stock of the |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 SAVARA INC. |
|
| June 7, 2024 |
Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St |
|
| May 20, 2024 |
SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047 SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047 May 20, 2024 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC, 20549 Re: Savara, Inc. Acceleration Request Registration Statement on Form S-3 File No. 333-279274 Dear Sir/Madam: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), |
|
| May 14, 2024 |
United States securities and exchange commission logo May 14, 2024 Matthew Pauls Chief Executive Officer Savara Inc. |
|
| May 9, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SAVARA INC. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| May 9, 2024 |
Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. (1) FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC (3) FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC. AND (4) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 12, 2024 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2024 SAVARA INC. |
|
| April 12, 2024 |
SVRA / Savara Inc. / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| March 7, 2024 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through February 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Comp |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| March 7, 2024 |
Exhibit 10.36 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 2 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 2 to the Manufacture and Supply Agreement (“Amendment No. 2”), dated December 13, 2023 ( |
|
| March 7, 2024 |
Power of Attorney is contained on the signature page As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0 |
|
| March 7, 2024 |
Exhibit 97 SAVARA INC. POLICY REGARDING THE MANDATORY RECOVERY OF COMPENSATION EFFECTIVE NOVEMBER 28, 2023 I. Applicability. This Policy Regarding the Mandatory Recovery of Compensation (the “Policy”) applies to any Incentive Compensation paid to Savara Inc.’s (the “Company”) Executive Officers. The Policy is intended to comply with and be interpreted in accordance with the requirements of Listing |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 SAVARA INC. |
|
| February 14, 2024 |
SVRA / Savara Inc. / Zambon Spa - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) January 24, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2024 |
SVRA / Savara Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the |
|
| February 13, 2024 |
SVRA / Savara Inc. / CAXTON CORP Passive Investment SC 13G/A 1 d1096525013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 13, 2024 |
SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G 1 sav.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3) SEC USE ONLY |
|
| February 8, 2024 |
SVRA / Savara Inc. / JENNISON ASSOCIATES LLC Passive Investment SC 13G 1 SVRA1223.txt Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of Issuer: Savara Inc. |
|
| February 7, 2024 |
SVRA / Savara Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment SC 13G/A 1 p24-0475sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo |
|
| February 1, 2024 |
SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 svra13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 31, 2024 |
SVRA / Savara Inc. / BlackRock Inc. Passive Investment SC 13G 1 us8051111016013124.txt us8051111016013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2024 SAVARA INC. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 SAVARA INC. |
|
| January 5, 2024 |
EX-99.1 Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2024 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe, |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| July 26, 2023 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| July 25, 2023 |
SVRA / Savara Inc / TCG Crossover GP I, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) July 17, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| July 25, 2023 |
Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| July 19, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.H Exhibit H AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) joi |
|
| July 19, 2023 |
SVRA / Savara Inc / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| July 13, 2023 |
EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: July 17, 2023 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2023 SAVARA INC. |
|
| July 13, 2023 |
EX-1.1 Exhibit 1.1 21,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT July 12, 2023 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladi |
|
| July 13, 2023 |
EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pennsylvania – July 13, 2023 – Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share |
|
| July 13, 2023 |
21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257709 PROSPECTUS SUPPLEMENT (To Prospectus dated July 16, 2021) 21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock We are offering 21,000,000 shares of our common stock, $0.001 par value per share, in this offering. We are also offering to certain of our existing large inv |
|
| June 16, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. |
|
| June 16, 2023 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through June 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of th |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 S-8 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 9, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC. |
|
| June 8, 2023 |
EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases June 2023 Exhibit 99.1 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” |
|
| May 15, 2023 |
LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”), effective as of the 7th day of July, 2021 (the “Effective Date”), is made by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| May 15, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “Amendment”) is made this 28th day of February, 2023 (the “Effective Date”), by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord and Tenant entered into a certain written Agreement of Lease dated July 7, 2021 (the “O |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| March 30, 2023 |
Exhibit 10.33 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 1 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 1 to the Manufacture and Supply Agreement (“Amendment No. 1”), dated December 7, 2022 (“ |
|
| March 30, 2023 |
Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% SD Pharmaceuticals, Inc. 100% Aires Pharmaceuticals, Inc. 100% |
|
| March 30, 2023 |
Savara Inc. Amended and Restated 2015 Omnibus Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. AMENDED AND RESTATED 2015 OMNIMBUS INCENTIVE PLAN (as amended by the Board through March 8, 2023, subject to stockholder approval) Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effective Date. 1. PURPOSE OF THIS PLAN The purp |
|
| March 30, 2023 |
Exhibit 10.29 DocuSign Envelope ID: 8B2E51B6-69B8-42A7-9E84-016D2871D63E October 26, 2022 FIRST AMENDMENT TO LEASE AGREEMENT Re: Lease Agreement dated May 11, 2021, by and between Overlook at Rob Roy Owner, LLC, as Lessor, and Savara, Inc., as Lessee, consisting of approximately 2,260 rentable square feet of space locally known as Suite III- 201 at 6836 Bee Caves Road, Austin, Travis County, Texas |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SAVARA INC. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.2 Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through March 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of t |
|
| March 30, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SAVARA INC. (a Delaware corporation) March 28, 2023 ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Savara Inc. (the “corporation”) shall be fixed in the Certificate of Incorporation of the corporation. 1.2 OTHER OFFICES. The board of directors may at any time establish the principal office and any branch or subordinate |
|
| March 30, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. |
|
| March 30, 2023 |
Exhibit 10.34 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 10, 2022 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Raymond D. Pratt, M.D. (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Medical Officer pursuant to the terms of this Agreement. NOW, THEREF |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 SAVARA INC. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 SAVARA INC. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 SAVARA INC. |
|
| February 14, 2023 |
Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of February 13, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Rob Lutz (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Operating Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in consi |
|
| February 14, 2023 |
SVRA / Savara Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236584d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| January 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0 |
|
| January 20, 2023 |
EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through December 13, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary |
|
| January 20, 2023 |
As filed with the Securities and Exchange Commission on January 20, 2023 S-8 As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. |
|
| December 15, 2022 |
Exhibit 10.2 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and David Lowrance (?Executive?). This Agreement amends and restates and supersedes in its entirety the Executive Employment Agreement dated |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2022 SAVARA INC. |
|
| December 15, 2022 |
Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Matthew Pauls (?Executive?). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm |
|
| November 21, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. |
|
| November 21, 2022 |
As filed with the Securities and Exchange Commission on November 21, 2022 S-8 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No. |
|
| November 21, 2022 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021 and September 8, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2022 SAVARA INC. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 SAVARA INC. |
|
| May 11, 2022 |
Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?), and provides the terms on which Bank shall lend to Borrower, and Borrower shall repay Bank. This Agreement a |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2022 SAVARA INC. |
|
| April 19, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| March 30, 2022 |
Exhibit 10.17 SAVARA INC. RESTRICTED STOCK UNIT AGREEMENT (INDUCEMENT AWARD) NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the ?Award?) pursuant to this Agreement and the Savara Inc. 2021 Inducement Equity Plan (the ?Plan?), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of S |
|
| March 30, 2022 |
Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company. |
|
| March 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0 |
|
| March 30, 2022 |
Exhibit 10.16 SAVARA INC. NON-STATUTORY STOCK OPTION AGREEMENT (INDUCEMENT AWARD) THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Grantee?). 1. Grant of Option. The Company hereby grants to the Grantee a non-statutory stock option (the ?Optio |
|
| March 30, 2022 |
Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% Savara Australia Pty Limited 100% Aires Pharmaceuticals, Inc. 100% SD Pharmaceuticals, Inc. 100% |
|
| March 30, 2022 |
Power of Attorney is contained on the signature page. As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| February 14, 2022 |
SVRA / Savara Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
SVRA / Savara Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 10, 2022 |
SVRA / Savara Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2022 SAVARA INC. |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2022 SAVARA INC. |
|
| January 10, 2022 |
Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2022 Exhibit 99. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| July 14, 2021 |
Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021 Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Savara Inc. Registration Statement on Form S-3 Filed July 6, 2021 File No. 333-257709 Acceleration Request Requested Date: July 16, 2021 Requested Time: 4:00 p.m. (Eastern time), or as soon t |
|
| July 12, 2021 |
United States securities and exchange commission logo July 12, 2021 Matthew Pauls Chief Executive Officer Savara Inc. |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2021 SAVARA INC. |
|
| July 6, 2021 |
Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows. 1. |
|
| July 6, 2021 |
Savara Inc. 2021 Inducement Equity Incentive Plan Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of |
|
| July 6, 2021 |
Exhibit 4.4 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1. Designation and Terms of Securities 5 Section 2.2. Form of Securities and Trustee?s Certificate 7 Section 2. |
|
| July 6, 2021 |
Exhibit 1.2 Execution Version SAVARA INC. SHARES OF COMMON STOCK (PAR VALUE $0.001 PER SHARE) SALES AGREEMENT July 6, 2021 Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 Ladies and Gentlemen: SAVARA INC., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with EVERCORE GROUP L.L.C. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Company ag |
|
| July 6, 2021 |
As filed with the Securities and Exchange Commission on July 6, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 6, 2021 Registration No. |
|
| July 6, 2021 |
Form of Subordinated Indenture Exhibit 4.5 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2.2 Form of Securities and Trustee?s Certificate 7 Section |
|
| July 6, 2021 |
As filed with the Securities and Exchange Commission on July 6, 2021 As filed with the Securities and Exchange Commission on July 6, 2021 Registration No. |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 SAVARA INC. |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2021 SAVARA INC. |
|
| June 14, 2021 |
Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St |
|
| June 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 SAVARA INC. |
|
| June 4, 2021 |
Exhibit 10.1 BASIC LEASE INFORMATION The following Basic Information is incorporated into and made a part of this lease. Each reference in this lease to any of the Basic Lease Information shall mean the respective information set forth below and shall be construed to incorporate all of the terms provided under the particular lease paragraph(s) pertaining to such information. In the event of a conf |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc |
|
| May 13, 2021 |
Exhibit 10.5 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [***] indicates where such information has been omitted. Parexel Project # [***] WORK ORDER This Work Order #1 (this ?Work Order?) is by and between Savara Inc. (?Client?) |
|
| May 13, 2021 |
Exhibit 10.4 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Services Agreement (this ?Agreement?) is effective as of January 6, 2021 (the |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the |
|
| April 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the |
|
| April 12, 2021 |
us8051111016040921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) March 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 SAVARA INC. |
|
| April 1, 2021 |
Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 30, 2021, by and among SILICON VALLEY BANK, a California corporation (?Bank?), SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (?Parent?), and ARAVAS INC. f/k/a SAVARA INC., a Delaware corporation (each a ?Co-Borrower? an |
|
| March 25, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A |
|
| March 25, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) March 15, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 17, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| March 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2021 SAVARA INC. |
|
| March 16, 2021 |
EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) March 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Suc |
|
| March 12, 2021 |
45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2018) 45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock We are offering 45,785,828 shares of our common stock, $0.001 par value per share, at a purchase price of $1.45 per share in this offering. We are also offering to |
|
| March 11, 2021 |
Exhibit 1.1 45,785,828 Shares of Common Stock and Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT March 11, 2021 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies an |
|
| March 11, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2021 SAVARA INC. |
|
| March 11, 2021 |
Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [?] Number of Shares: [?] (subject to adjustment) Original Issue Date: March [?], 2021 Savara Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its permitted registered assigns (the ?Hold |
|
| March 11, 2021 |
SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AUSTIN, TX – March 11, 2021 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offere |
|
| March 11, 2021 |
Exhibit 10.1 FORM OF WARRANT REPURCHASE AGREEMENT THIS WARRANT REPURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of March [?], 2021 by and among Savara Inc., a Delaware corporation (the ?Company?), and the entities listed on Exhibit A (each, a ?Seller?). WHEREAS, each Seller owns a warrant dated December 24, 2019 (the ?Warrant?) to purchase the number of shares of the Company?s Co |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2021 SAVARA INC. |
|
| March 10, 2021 |
Exhibit 10.9 Savara Inc. 2015 Omnibus Incentive Plan Incentive Stock Option Grant Agreement ? Exempt Employees THIS INCENTIVE STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?). 1.Grant of Option. The Company hereby grants to the Participant [NUMBER] |
|
| March 10, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 10, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| March 10, 2021 |
Executive Employment Agreement, dated March 9, 2021, between Savara Inc. and Badrul Chowdhury Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of March 9, 2021 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Badrul Chowdhury (?Executive?). WHEREAS, Executive is currently employed by the Company as the Company?s Chief Medical Officer pursuant to the terms of an offer letter agreement dated |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 2, 2021 |
us8051111016020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2021 SAVARA INC. |
|
| January 19, 2021 |
EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) January 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. S |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2020 SAVARA INC. |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2020 SAVARA INC. |
|
| December 10, 2020 |
Exhibit 99.1 SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex i |
|
| December 10, 2020 |
EX-10.1 2 d38434dex101.htm EX-10.1 Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of December 8, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). This Agreement amends and restates and supersedes in its entirety the Exec |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2020 SAVARA INC. |
|
| September 11, 2020 |
Executive Employment Agreement, dated September 11, 2020, between Savara Inc. and Matthew Pauls EX-10.1 2 d34590dex101.htm EX-10.1 Exhibit 10.1 Execution Version SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of September 11, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chairman and Interim CEO pursu |
|
| September 11, 2020 |
EX-99.1 3 d34590dex991.htm EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, TX – Sept. 11, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CE |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 SAVARA INC. |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc. |
|
| August 6, 2020 |
EX-99.1 2 d26703dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 AUSTIN, TX – August 6, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today |
